Special Report: Medical cannabis stock Creso is set to start selling products in Canada.  

Creso Pharma (ASX:CPH) says its Canadian subsidiary Mernova Medicinal Inc will soon be able to offer high quality cannabis products to the retail recreational and medical markets.

Mernova received it’s sales licence from Health Canada earlier this year, and Creso Pharma has completed its legal due diligence on the activities that are authorised under the licence.

The ability to sell products directly into the medicinal and rapidly growing recreational markets in Canada is an important commercial development for Mernova.

Mernova will soon be able to offer high quality cannabis products to the retail recreational and medical market

“We are pleased to have completed this due diligence process very quickly as it now allows us to shift our attention back to selling our high-quality cannabis products,” Creso Pharma CEO and Co-Founder Dr Miri Halperin Wernl said.

“Mernova has an exciting opportunity ahead to cement a robust retail footprint in what is a rapidly expanding Canadian market and we are moving promptly to capture this value for our shareholders.

“I look forward to providing further updates on sales progress over the coming weeks.”

This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreCannabisCannabis StocksMedical Cannabis

Featured Companies

You might be interested in